Answer
Women of child-bearing potential should use effective contraception during ublituximab treatment and for at least 4 months after the last infusion.
Sources for this answer
- Briumvi 150 mg concentrate for solution for infusionNeuraxpharm UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked